Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Sparano

Showing results (171-180 of 293) with videos related to

Pageof 30
Sort By:
Blood|November 20, 2004
Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trialsMichele Spina, Ulrich Jaeger, Joseph A Sparano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanomaM B Atkins, K R O'Boyle, J A Sosman, et al.
Cancer Chemotherapy and Pharmacology|October 29, 2010
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancerAllyson J Ocean, Paul Christos, Joseph A Sparano, et al.
The Lancet. Oncology|June 2, 2012
A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpointsDebora Fumagalli, Philippe L Bedard, Zeina Nahleh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancerKathy D Miller, Thomas J Saphner, David M Waterhouse, et al.
Cancer|October 16, 2012
Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 yearsAmye J Tevaarwerk, Robert J Gray, Bryan P Schneider, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1994
Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumorsJ A Sparano, R I Fisher, G R Weiss, et al.
Breast Cancer Research and Treatment|August 7, 2024
Monitoring of estradiol levels in premenopausal women receiving adjuvant abemaciclib and ovarian function suppressionAlaina J Kessler, Rima Patel, Emily Jane Gallagher, et al.
Clinical Breast Cancer|July 7, 2011
Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancerAyca Gucalp, Joseph A Sparano, James Caravelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2023
Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)Missak Haigentz, Jeannette Y Lee, Elizabeth Y Chiao, et al.
Pageof 30

Showing results (171-180 of 293) with videos related to

Sort By:
Pageof 30
Blood|November 20, 2004
Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trialsMichele Spina, Ulrich Jaeger, Joseph A Sparano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanomaM B Atkins, K R O'Boyle, J A Sosman, et al.
Cancer Chemotherapy and Pharmacology|October 29, 2010
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancerAllyson J Ocean, Paul Christos, Joseph A Sparano, et al.
The Lancet. Oncology|June 2, 2012
A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpointsDebora Fumagalli, Philippe L Bedard, Zeina Nahleh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancerKathy D Miller, Thomas J Saphner, David M Waterhouse, et al.
Cancer|October 16, 2012
Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 yearsAmye J Tevaarwerk, Robert J Gray, Bryan P Schneider, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1994
Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumorsJ A Sparano, R I Fisher, G R Weiss, et al.
Breast Cancer Research and Treatment|August 7, 2024
Monitoring of estradiol levels in premenopausal women receiving adjuvant abemaciclib and ovarian function suppressionAlaina J Kessler, Rima Patel, Emily Jane Gallagher, et al.
Clinical Breast Cancer|July 7, 2011
Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancerAyca Gucalp, Joseph A Sparano, James Caravelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2023
Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)Missak Haigentz, Jeannette Y Lee, Elizabeth Y Chiao, et al.
Pageof 30